Journal profile · ORTHOPEDICS
Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders
ISSN 1179-5441 · SAGE Publishing · United Kingdom
Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.2 (journal website); fully open access; APC about USD 4,150; median 214 days to acceptance (32 articles, last 24 months); acceptance rate 34.5% (journal website); 14 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders is published by SAGE Publishing and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Osteoarthritis Treatment and Mechanisms, Rheumatoid Arthritis Research and Therapies and Total Knee Arthroplasty Outcomes, together about 37% of its articles. Its main subfields are Rheumatology and Surgery. (generated from OpenAlex topic counts and CAS ranking data)
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders is an international, peer reviewed journal focusing on all aspects of the prevention, diagnosis and management of arthritis and autoimmune disease and diseases of the bones and … | View full journal description This journal is a member of the Committee on Publication Ethics (COPE).
From the journal's Aims & Scope
Research area (LetPub): ORTHOPEDICS
Editor-in-chief Chuanju LiuPublisher website
Editorial board by country: none in mainland China; most named United States 12, United Kingdom 1, Japan 1, India 1, France 1 (20 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Osteoarthritis Treatment and MechanismsMedicine16.5%
- Rheumatoid Arthritis Research and TherapiesMedicine13.2%
- Total Knee Arthroplasty OutcomesMedicine7.3%
- Systemic Lupus Erythematosus ResearchMedicine5.4%
- Tendon Structure and TreatmentMedicine4.6%
- Spondyloarthritis Studies and TreatmentsMedicine4.1%
- Autoimmune and Inflammatory Disorders ResearchMedicine4.1%
- Shoulder Injury and TreatmentMedicine3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Orthopedics | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Orthopedics | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 1.2Publisher website ·
- 5-year impact factor (publisher)
- 1.7Publisher website ·
- CiteScore 2026-06
- 3.2LetPub ·
- SJR 2026-06
- 0.41LetPub ·
- SNIP 2026-06
- 0.91LetPub ·
- h-index
- 33OpenAlex ·
- i10-index
- 112OpenAlex ·
- 2-year mean citedness
- 0.85OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 13LetPub ·
- Articles per year (publisher)
- 3Publisher website ·
Articles by year OpenAlex count · 246 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 18 | 18 | 5 |
| 2025 | 14 | 14 | 6 |
| 2024 | 9 | 9 | 24 |
| 2023 | 11 | 11 | 53 |
| 2022 | 14 | 14 | 158 |
| 2021 | 11 | 11 | 122 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
214 daysMedian, submission to acceptance · P25–P75 173 days – 252 days
- Acceptance to online
- median 35 days (32 articles)
- Submission to online
- median 260 days
- Sample
- 32 articles with submission and acceptance dates (34 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 8 weeksLetPub ·
- Acceptance rate (publisher)
- 34.5%Publisher website ·
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 114 daysPublisher website ·
- Submission to acceptance
- 217 daysPublisher website ·
- Acceptance to publication
- 37 daysPublisher website ·
- Peer review
- Blind peer reviewLetPub
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,150 / GBP 3,043 | — | — | |
| LetPub | USD 1,848 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- ≤ 300 words
- Manuscript length
- ≤ 6,000 words
- Reference style
- Vancouver
- First submission
- Free format: the journal's layout is not required
- Suggested reviewers
- Required
Article types accepted5
- perspectivePlease visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstracts. Clinical Medicine Insights: Arthritis and Musculoskeletal …Length not stated
- research articlePlease visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstracts. Clinical Medicine Insights: Arthritis and Musculoskeletal …Length not stated
- reviewPlease visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstracts. Clinical Medicine Insights: Arthritis and Musculoskeletal …Length not stated
- review articlePlease visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstracts. Clinical Medicine Insights: Arthritis and Musculoskeletal …Length not stated
- systematic reviewPlease visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstracts. Clinical Medicine Insights: Arthritis and Musculoskeletal …Length not stated
Policy excerpts from the journal's websiteAuthorship, Data availability, Publication ethics, License & copyright, Open access, Peer review, Plagiarism, Preprints, Trial registration / reporting guidelines
- Authorship Author contributions
You will be asked to list the contribution of each author as part of the submission process. Please include the Author Contributions heading within your submission after the Acknowledgements section. The information you give on submission will then show under the Author Contributions heading later at the proofing stage.
Source ↗Publisher website ·- Data availability Data availability
The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…
Source ↗Publisher website ·- Publication ethics Ethical considerations
Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…
Source ↗Publisher website ·- License & copyright
Manuscript content on this site is licensed under Creative Commons Licenses Model summary
Manuscript content on this site is licensed under Creative Commons Licenses
Source ↗Publisher website ·- Open access Publishing fees and open access
There are no fees payable to submit or publish in this journal. Figures submitted in color will be published in color in the online version of the journal at no cost. If you wish to have color figures in the printed version, colour printing charge to be determined at production stage. Optional open access publishing is available for a fee via the Sage Choice program, and Open Access agreements, wh…
Source ↗Publisher website ·- Peer review Peer review policy
The following summary describes the peer review process for this journal: Identity transparency: Single-anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk rejec…
Source ↗Publisher website ·- Plagiarism Plagiarism
The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.
Source ↗Publisher website ·- Preprints Preprints
The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical trial registration
The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- SAGE Publishing
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 1179-5441
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders
What CAS zone is Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders is in Zone 4 of Medicine, and in Zone 4 of the minor category Orthopedics. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders?
The journal's website gives an impact factor of 1.2; this is the journal's own figure, as LetPub lists none for it; CiteScore 3.2, h-index 33.
How long does peer review take at Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders?
Based on the dates recorded on 32 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 214 days (interquartile range 173–252 days); authors report an average review time of about 8 weeks; the journal's website gives an acceptance rate of 34.5%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders?
According to the journal's author guidelines: Abstract: ≤ 300 words; Manuscript length: ≤ 6,000 words; Reference style: Vancouver; First submission: Free format: the journal's layout is not required; Suggested reviewers: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders based?
Of the 20 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (12), United Kingdom (1) and Japan (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders?
According to LetPub and DOAJ records, Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders is indexed in ESCI and Scopus.
Is Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders open access, and what is the APC?
Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders is a fully open-access journal. APC about USD 4,150.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .